Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

被引：2

作者：

Ionova, Tatyana ^{[1
,2
]}

Afanasiev, Boris ^{[3
]}

Andrievskih, Maria ^{[4
]}

Amdiev, Alim ^{[5
]}

Baryakh, Elena A. ^{[6
]}

Chang, Viktor ^{[7
]}

Husainova, Gulnara ^{[8
]}

Ivanov, Vladimir ^{[9
]}

Kaplanov, Kamil D. ^{[10
]}

Kaverina, Oksana ^{[11
]}

Klitochenko, Tatiana ^{[10
]}

Kurakin, Vyacheslav ^{[12
]}

Larionova, Olga ^{[13
,16
,18
]}

Lazareva, Darya ^{[11
]}

Lepik, Kirill ^{[14
]}

Lysenko, Irina ^{[15
]}

Mikhailova, Nataliia ^{[14
]}

Minullina, Raisa ^{[8
]}

Mironov, Oleg

Misyurina, Elena ^{[6
]}

Mochkin, Nikita ^{[17
]}

Nikitina, Tatiana ^{[1
,2
]}

Osipov, Iurii ^{[9
]}

Petrova, Tatiana ^{[8
]}

Porfirieva, Natalia ^{[1
]}

Rykavitcin, Oleg

Safin, Rustem ^{[8
]}

Shelekhova, Tatiana ^{[19
]}

Sherstnev, Dmitrij ^{[19
]}

Simashova, Polina ^{[18
]}

Smirnova, Elena ^{[17
]}

Trenina, Natalia ^{[12
]}

Vasiliev, Evgeniy V. ^{[20
]}

Volkov, Mikhail ^{[13
]}

Volodicheva, Elena ^{[21
]}

机构：

[1] Multinatl Ctr Qual Life Res, St Petersburg, Russia

[2] St Petersburg State Univ Hosp, St Petersburg, Russia

[3] First State Pavlov Med Univ St Petersburg, Raisa Gorbacheva Mem Res Inst Paediat Oncol Hemat, St Petersburg, Russia

[4] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[5] VM Efetov Crimean Republican Oncol Ctr, Simferopol, Ukraine

[6] City Clin Hosp 52, Moscow, Russia

[7] Tambov Reg Oncol Clin Ctr, Tambov, Russia

[8] Minist Hlth Republ Tatarstan, Republican Clin Oncol Ctr, Kazan, Russia

[9] Almazov Natl Med Res Ctr, St Petersburg, Russia

[10] Reg Clin Oncol Dispencary, Volgograd, Russia

[11] Altai Reg Oncol Ctr, Barnaul, Russia

[12] Clin Oncol Ctr, Omsk, Russia

[13] Primorskiy Reg Oncol Ctr, Vladivostok, Russia

[14] Pavlov First St Petersburg State Med Univ, Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg, Russia

[15] Rostov Sci Res Inst Oncol, Rostov Na Donu, Russia

[16] Tambov Reg Oncol Clin Ctr, Tambov, Russia

[17] NI Pirogov Natl Med Surg Ctr, Moscow, Russia

[18] NN Burdenko Principal Mil Clin Hosp, Moscow, Russia

[19] Saratov State Med Univ, Clin Profess Pathol & Hematol, Saratov, Russia

[20] Reg Clin Hosp, Krasnoyarsk, Russia

[21] Reg Clin Hosp, Tulsa, Russia

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-121997

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5296

引用

页数：4

共 50 条

[21] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
Angelopoulou, Maria K.
Vassilakopoulos, Theodoros P.
Batsis, Ioannis
Sakellari, Ioanna
Gkirkas, Konstantinos
Pappa, Vasiliki
Giannoulia, Panagiota
Apostolidis, Ioannis
Apostolopoulos, Christos
Roussou, Paraskevi
Panayiotidis, Panayiotis
Dimou, Maria
Kyrtsonis, Marie-Christine
Palassopoulou, Maria
Vassilopoulos, Georgios
Moschogiannis, Maria
Kalpadakis, Christina
Margaritis, Dimitrios
Spyridonidis, Alexander
Michalis, Eurydiki
Anargyrou, Konstantinos
Repousis, Panagiotis
Hatzimichael, Eleutheria
Bousiou, Zoi
Poulakidas, Elias
Grentzelias, Dimitrios
Harhalakis, Nikolaos
Pangalis, Gerassimos A.
Anagnostopoulos, Achilles
Tsirigotis, Panagiotis
HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 174 - 181
[22] BRENTUXIMAB VEDOTIN (BV) AN EFFECTIVE TREATMENT FOR TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)
Viviani, S.
Guidetti, A.
Dalto, S.
Dodero, A.
Farina, L.
Bolis, S.
Rigacci, L.
Zallio, F.
Busca, A.
Bruno, B.
Mordini, N.
Parvis, G.
Corradini, P.
HAEMATOLOGICA, 2015, 100 : 455 - 456
[23] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Herrera, Alex F.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zhang, Qu
Kato, Kazunobu
Campbell, Mary
Advani, Ranjana H.
BLOOD, 2018, 131 (11) : 1183 - 1194
[24] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
Zhi-Gang Cao
Hong-Wei Zhou
Chao-Jin Peng
Mo Liu
Yu Du
Qing-Ming Yang
ChineseJournalofCancer, 2013, 32 (09) : 520 - 523
[25] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: SINGLE CENTER EXPERIENCE
Valiev, Timur
Tsaplina, Nataly
Kirgizov, Kirill
PEDIATRIC BLOOD & CANCER, 2022, 69 : S589 - S589
[26] Importance of consolidation in patients with relapsed/refractory Hodgkin's lymphoma responders to Brentuximab Vedotin
Machet, Antoine
Cayssials, Emilie
Leleu, Xavier
Guidez, Stephanie
HEMATOLOGIE, 2016, 22 (04): : 248 - +
[27] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
Forlenza, Christopher J.
Rosenzweig, Jaclyn
Mauguen, Audrey
Buhtoiarov, Ilia
Cuglievan, Branko
Dave, Hema
Deyell, Rebecca J.
Flerlage, Jamie E.
Franklin, Anna K.
Krajewski, Jennifer
Leger, Kasey J.
Marks, Lianna J.
Norris, Robin E.
Pacheco, Martha
Willen, Faye
Yan, Adam Paul
Harker-Murray, Paul D.
Giulino-Roth, Lisa
BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
[28] Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin
Faulk, Kelly E.
Sopfe, Jenna M.
Campbell, Kristen
Liptzin, Deborah R.
Liu, Arthur K.
Franklin, Anna R. K.
Cost, Carrye R.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 251 - 256
[29] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
Tsirigotis, P.
Vassilakopoulos, T.
Bousiou, Z.
Mpatsis, I.
Gkirkas, K.
Sakellari, I.
Papageorgiou, S.
Roussou, P.
Pangalis, G.
Galani, Z.
Moschoyianni, M.
Vassilopoulos, G.
Repoussis, P.
Megalakaki, E.
Michalis, E.
Anagnostopoulos, N.
Calpadaki, C.
Papadaki, H.
Margaritis, D.
Chatzimichail, E.
Briassoulis, E.
Spyridonidis, A.
Grentzelias, D.
Anargyrou, K.
Tsionos, K.
Mpanti, A.
Poulakidas, E.
Palaska, C.
Gribabi, D.
Apostolidis, J.
Pappa, V.
Harhalakis, N.
Panayiotidis, P.
Konstantopoulos, K.
Anagnostopoulos, A.
Angelopoulou, M.
HAEMATOLOGICA, 2015, 100 : 454 - 455
[30] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
Ulu, Bahar Uncu
Dal, Mehmet Sinan
Hindilerden, Ipek Yonal
Akay, Olga Meltem
Mehtap, Ozgur
Buyukkurt, Nurhilal
Hindilerden, Fehmi
Gunes, Ahmet Kursad
Yigenoglu, Tugce Nur
Basci, Semih
Cakar, Merih Kizil
Acik, Didar Yanardag
Korkmaz, Serdal
Ulas, Turgay
Ozet, Gulsum
Ferhanoglu, Burhan
Nalcaci, Meliha
Altuntas, Fevzi
JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198

← 1 2 3 4 5 →